Hanstock et al. (90) observed that patients affected by upper respiratory tract infection had a significantly lower concentration of tear lysozyme and/or lactoferrin compared to healthy volunteers, suggesting that lysozyme and lactoferrin may serve as clinically relevant biomarkers for mucosal immune competence. This evidence concerns the gene LYZ and Recurrent upper respiratory tract infections.